Treatment of adult-onset Langerhans cell histiocytosis--is it different from the pediatric approach?
Gadner
H
H
Department of Hemato/Oncology, St Anna Children's Hospital, Vienna, Austria. Electronic address: h.gadner@stanna.at.
D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010372:Pediatrics / Q000379:methods; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate